A Microdose Evaluation Study of ABY-029 in Head and Neck Oncology Surgery

Summary

The primary study objective is to determine if microdoses of ABY-029 (up to 6X) lead to detectable signals (defined as signal-to-noise ratio, SNR ≥10, with wide-field iFI) in sampled tissues with an EGFR (epidermal growth factor receptor) pathology score ≥ 1 based on histological staining. The secondary study objective is to assess ex vivo the specificity of tumor binding in resected specimens by measuring the corresponding molecular uptake and concentrations using histopathology.

Timeline

Start

2018-01-24

Primary completion

2020-12-18

Completion

2020-12-18

Drugs

Indications